Elekta (EKTA) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
26 Nov, 2025Executive summary
Strong performance in Europe, driven by new product launches and double-digit growth, while a new CEO emphasized execution and commercial turnaround, especially in the U.S.
A new decentralized operating model was announced, including a 10% workforce reduction (about 450 positions, mainly managerial) and targeted annual cost savings of at least SEK 500 million, with full impact expected by Q1 2026/27.
Comprehensive order backlog review led to SEK 2.2 billion in cancellations, mainly in Middle East and Africa, with no expected impact on revenue or cash flow.
Cash flow after continuous investments improved significantly year-over-year, reaching SEK 358 million, supported by better working capital and lower investments.
Further strategy updates and details to be provided at Capital Markets Day in June.
Financial highlights
Q2 organic revenue/net sales grew 1% in constant currency, with Europe up 11%, while reported sales declined 6% due to FX; Americas fell 8%, APAC declined 3% with growth in India offset by China.
Adjusted gross margin improved to 37.9% (up 2.2 ppts year-over-year), and adjusted EBIT margin rose to 10.1% (up 0.3 ppts); adjusted EPS at SEK 0.65.
Net income for the quarter was SEK 229 million, up 6% year-over-year.
Cash conversion reached 91%, up from 65% a year ago.
Net debt reduced by almost SEK 700 million year-over-year, with net debt/EBITDA at 1.22.
Outlook and guidance
Full-year 2025/26 outlook reiterated: net sales in constant currency expected to grow year-over-year.
Sales in China expected to recover in H2 2025/26, with continued negative impact from tariffs and FX at current rates.
Midterm targets include gross margin returning to pre-pandemic levels and EBIT margin reaching 14% or higher; more details to be shared at Capital Markets Day.
Latest events from Elekta
- Adjusted gross margin rose to 38.3% as restructuring costs and FX reduced net income.EKTA
Q3 20265 Mar 2026 - SEK 500m+ savings, job cuts, and innovation drive target growth in China and US.EKTA
Strategy update2 Feb 2026 - Sales up 5% year-over-year, but Q4 declined; margin recovery expected in H2 2024/25.EKTA
Q4 23/2431 Jan 2026 - Net sales up 1% with strong U.S. growth and a major Mexico order; margin recovery expected.EKTA
Q1 24/2523 Jan 2026 - Sales and margins declined, but new products and cost savings are set to boost performance.EKTA
Q2 24/2512 Jan 2026 - AI-driven adaptive radiotherapy and software boost growth, margins, and global adoption.EKTA
Investor update10 Jan 2026 - Record cash flow and European growth offset US and China weakness; margin guidance lowered.EKTA
Q3 24/2527 Dec 2025 - Net sales up 3% in constant currency, margins down, net income up 50%, cash flow improved.EKTA
Q1 25/2623 Nov 2025 - Margin expansion, software growth, and profitable orders drive confidence in mid-term targets.EKTA
Investor update21 Nov 2025